Dextromethorphan-Bupropion Significantly Improves Major Depression Symptoms in Phase 2 ASCEND

Via Peters

Investigative therapy dextromethorphan-bupropion (AXS-05) provided significantly improved major depression symptoms versus lone sustained-release bupropion while remaining tolerable in adult patients over 6 weeks, according to new phase 2 trial findings. In a randomized, double-blind, multi center, parallel-group study of the NMDA/sigma-1 receptor antagonist combination therapy, investigators observed significant improvements in […]

Patient Race Doesn’t Significantly Impact Pathological CR After Neoadjuvant Therapy for Breast Cancer

Via Peters

Although significant disparities for a subgroup of women who did not achieve a pathologic complete response (pCR) were observed, patient race did not significantly impact pCR and event-free survival (EFS) in patients with high-risk breast cancer who received targeted neoadjuvant chemotherapy, according to results presented by Beverly Kyalwazi, BS, at […]